205 related articles for article (PubMed ID: 7530378)
1. The dopamine-serotonin relationship in clozapine response.
Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T
Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378
[TBL] [Abstract][Full Text] [Related]
2. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.
Scheepers FE; Gispen-de Wied CC; Westenberg HG; Kahn RS
Neuropsychopharmacology; 2001 Oct; 25(4):468-75. PubMed ID: 11557160
[TBL] [Abstract][Full Text] [Related]
3. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
[TBL] [Abstract][Full Text] [Related]
4. Interactions between central monoaminergic systems: dopamine-serotonin.
Roccatagliata G; Albano C; Cocito L; Maffini M
J Neurol Neurosurg Psychiatry; 1979 Dec; 42(12):1159-62. PubMed ID: 160445
[TBL] [Abstract][Full Text] [Related]
5. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
[TBL] [Abstract][Full Text] [Related]
6. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
[TBL] [Abstract][Full Text] [Related]
7. Clozapine therapy and increases in homovanillic acid.
Risch SC
Arch Gen Psychiatry; 1995 Mar; 52(3):244. PubMed ID: 7532936
[No Abstract] [Full Text] [Related]
8. Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid.
Geracioti TD; Keck PE; Ekhator NN; West SA; Baker DG; Hill KK; Bruce AB; Wortman MD
Biol Psychiatry; 1998 Aug; 44(3):228-33. PubMed ID: 9693394
[TBL] [Abstract][Full Text] [Related]
9. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history.
Lindström LH
Psychiatry Res; 1985 Apr; 14(4):265-73. PubMed ID: 2410940
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
Pickar D; Owen RR; Litman RE; Konicki E; Gutierrez R; Rapaport MH
Arch Gen Psychiatry; 1992 May; 49(5):345-53. PubMed ID: 1375019
[TBL] [Abstract][Full Text] [Related]
11. Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication.
Risch SC; Lewine RR
Arch Gen Psychiatry; 1993 Aug; 50(8):670. PubMed ID: 7688212
[No Abstract] [Full Text] [Related]
12. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism.
Narayan M; Srinath S; Anderson GM; Meundi DB
Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):630-5. PubMed ID: 7687150
[TBL] [Abstract][Full Text] [Related]
13. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Gerlach J; Thorsen K; Fog R
Psychopharmacologia; 1975; 40(4):341-50. PubMed ID: 1096218
[TBL] [Abstract][Full Text] [Related]
14. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia.
Wieselgren IM; Lindström LH
Psychiatry Res; 1998 Nov; 81(2):101-10. PubMed ID: 9858027
[TBL] [Abstract][Full Text] [Related]
15. Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine.
Hatzimanolis J; Lykouras L; Markianos M; Oulis P
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1077-85. PubMed ID: 9829289
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat.
Mignot E; Laude D; Elghozi JL
J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472
[TBL] [Abstract][Full Text] [Related]
17. Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes.
Salomon RM; Kennedy JS; Johnson BW; Urbano Blackford J; Schmidt DE; Kwentus J; Gwirtsman HE; Gouda JF; Shiavi RG
Neuropsychopharmacology; 2005 Nov; 30(11):2082-91. PubMed ID: 15856079
[TBL] [Abstract][Full Text] [Related]
18. Clozapine pharmacology and tardive dyskinesia.
Lieberman J; Johns C; Cooper T; Pollack S; Kane J
Psychopharmacology (Berl); 1989; 99 Suppl():S54-9. PubMed ID: 2479047
[TBL] [Abstract][Full Text] [Related]
19. Age and Gender-Related Changes in Biogenic Amine Metabolites in Cerebrospinal Fluid in Children.
Kuśmierska K; Szymańska K; Rokicki D; Kotulska K; Jóźwiak S; Sykut-Cegielska J; Mierzewska H; Szczepanik E; Pronicka E; Demkow U
Adv Exp Med Biol; 2016; 878():73-82. PubMed ID: 26453071
[TBL] [Abstract][Full Text] [Related]
20. Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study.
Nisijima K; Ishiguro T
Biol Psychiatry; 1993 Jan; 33(1):45-8. PubMed ID: 7678377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
